As the mRNA push continues, Samsung will expand its drug substance manufacturing at South Korean hub
As the demand for mRNA capacity grows, Samsung Biologics has announced the addition of drug substance production capability to its facilities …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
